Calliditas Therapeutics announced that the FDA has accepted the submission for the supplemental New Drug Application, or sNDA, for Tarpeyo delayed release capsules and granted priority review. The Prescription Drug User Fee Act goal date is December 20.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CALT:
- Calliditas Therapeutics’ NefIgArd phase 3 trial results published in The Lancet
- Calliditas Therapeutics reports publication of NefIgArd Study data in The Lancet
- CALT Earnings this Week: How Will it Perform?
- Calliditas Therapeutics announces interim data from setanaxib trial
- Calliditas Therapeutics submits Tarpeyo sNDA to FDA
